Bausch Health Shares Slip After Phase 3 RED-C Trial Misses Primary Goal
Bausch Health Companies announced that its global Phase 3 RED-C program evaluating amorphous-rifaximin solid soluble dispersion (SSD) for primary prevention of hepatic encephalopathy did not meet the trial's primary endpoint. The result marks a material reversal for a program aimed at a large liver cirrhosis population and has contributed to recent…